Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
出版年份 2020 全文链接
标题
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
作者
关键词
-
出版物
DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-10-04
DOI
10.1002/dmrr.3413
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effects of SGLT2 Inhibitors on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Meta‐Analysis of Randomized Controlled Trials
- (2020) Baodi Xing et al. Journal of Diabetes Investigation
- Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2019) Yoshimasa Aso et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- C‐peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes
- (2019) Ningjian Wang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
- (2019) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Effects of Sodium Glucose Co‐transporter 2 Inhibitors on Serum Alanine Aminotransferase Values in Type 2 Diabetes Patients: A Multi‐Institutional Cohort Study
- (2019) Shih‐Chieh Shao et al. DIABETES OBESITY & METABOLISM
- Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults
- (2018) Tilman Kühn et al. BMC GASTROENTEROLOGY
- Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial
- (2018) Hiroyuki Takashima et al. Diabetes & Vascular Disease Research
- Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
- (2018) Alessandro Mantovani et al. DIABETES CARE
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study
- (2018) Yuya Tsurutani et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
- (2018) Noboru Kurinami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials
- (2018) Cyrielle Caussy et al. HEPATOLOGY
- The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice
- (2018) Dong Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW)
- (2018) Pia Christensen et al. DIABETES OBESITY & METABOLISM
- Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
- (2018) Teruki Miyake et al. Open Medicine
- A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
- (2018) Amedeo Lonardo et al. ACTA DIABETOLOGICA
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
- (2018) Mitsuko Inoue et al. Journal of Diabetes Investigation
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
- (2018) Yuya Seko et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial
- (2017) Kanako Kato et al. EXPERT OPINION ON PHARMACOTHERAPY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
- (2017) Yuya Seko et al. JOURNAL OF GASTROENTEROLOGY
- The epidemiology of non-alcoholic fatty liver disease
- (2017) Stefano Bellentani LIVER INTERNATIONAL
- Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
- (2017) Wenjie Dai et al. MEDICINE
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
- (2016) Giuseppe Daniele et al. DIABETES CARE
- Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men
- (2016) Takuya Fukuda et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
- (2016) Teruo Jojima et al. Diabetology & Metabolic Syndrome
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2016) Heidi Storgaard et al. PLoS One
- Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism
- (2015) Ruth C. Meex et al. Cell Metabolism
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- NAFLD: A multisystem disease
- (2015) Christopher D. Byrne et al. JOURNAL OF HEPATOLOGY
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers
- (2014) Sreeraj Macha et al. CLINICAL THERAPEUTICS
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
- (2014) T. Forst et al. DIABETES OBESITY & METABOLISM
- Gamma-Glutamyltransferase Fractions in Human Plasma and Bile: Characteristic and Biogenesis
- (2014) Irene Fornaciari et al. PLoS One
- Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea
- (2013) Guntram Schernthaner et al. DIABETES CARE
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
- (2013) F. J. Lavalle-González et al. DIABETOLOGIA
- Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis
- (2013) Ju Dong Yang et al. HEPATOLOGY
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
- (2013) J. P. H. Wilding et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)
- (2013) Siddharth Verma et al. LIVER INTERNATIONAL
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
- (2012) G. Musso et al. DIABETOLOGIA
- γ-Glutamyl transferase
- (2012) Diana Zaineff Banderas et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
- (2012) Christine Clar et al. BMJ Open
- Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
- (2011) E. Boettcher et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Endpoints and clinical trial design for nonalcoholic steatohepatitis
- (2011) Arun J. Sanyal et al. HEPATOLOGY
- Human Fatty Liver Disease: Old Questions and New Insights
- (2011) J. C. Cohen et al. SCIENCE
- Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c
- (2010) P. Ferré et al. DIABETES OBESITY & METABOLISM
- Menopause impacts the relation of plasma adiponectin levels with the metabolic syndrome
- (2009) P. Henneman et al. JOURNAL OF INTERNAL MEDICINE
- Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
- (2009) John Willy Haukeland et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes
- (2008) Anna Ludovica Fracanzani et al. HEPATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started